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oronary Artery Aneurysms After Drug-Eluting
tent Implantation
iro Aoki, MD, PHD, Ajay Kirtane, MD, SM, Martin B. Leon, MD, FACC,
eorge Dangas, MD, PHD, FACC
ew York, New York
rug-eluting stents (DES), which locally elute antiproliferative drugs, can dramatically inhibit neointimal
rowth. However, several pathological studies have indicated that DES may delay healing after vascular
njury, and DES implantation may be theoretically associated with a risk of coronary artery aneurysm for-
ation. Coronary aneurysms have been reported from 3 days to up to 4 years after DES implantation
rocedures, with varying clinical presentations. The incidence of coronary artery aneurysms after DES
mplantation is low within the ﬁrst 9 months, with a reported incidence of 0.2% to 2.3%, a rate similar to
hat reported after bare-metal stent (BMS) implantation (0.3% to 3.9%) in the DES versus BMS randomized
rials. However, the true incidence of coronary aneurysms in an unselected patient population is still largely
nknown. This article reviews the published literature on coronary artery aneurysms speciﬁcally relating to
ES. (J Am Coll Cardiol Intv 2008;1:14–21) © 2008 by the American College of Cardiology Foundationm
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eoronary artery aneurysms after coronary interven-
ion are rare, with a reported incidence of 0.3% to
.0%, and most “aneurysms” are in fact pseudoaneu-
ysms rather than true aneurysms (1–4). Residual
issection and deep arterial wall injury (rupture or
esection of the vessel media) caused by oversized
alloons or stents, high-pressure balloon inflations,
therectomy, and laser angioplasty have all been
ssociated with coronary artery aneurysms after cor-
nary intervention (1–3). Drug-eluting stents (DES),
hich locally elute antiproliferative drugs, can dra-
atically inhibit neointimal growth, thereby sup-
ressing restenosis (5,6), but at the same time poten-
ially causing coronary aneurysms due to other
echanisms, such as delayed re-endothelialization,
nflammatory changes of the medial wall, and hyper-
ensitivity reactions (7–10). These findings may be
ue to delayed healing secondary to the antiprolifera-
ive action of the eluted drug, cell necrosis and/or
poptosis from the antimetabolite effect of the drug,
nd hypersensitivity reactions to the drug/polymer
rom Columbia University Medical Center, the Cardiovascular Research
oundation, New York, New York.i
anuscript received September 14, 2007; revised manuscript received
ctober 2, 2007, accepted October 15, 2007.ixture on the DES (7–9). Given these findings as
ell as the described association of coronary artery
neurysm formation with systemic administration of
nti-inflammatory agents (glucocorticoids and col-
hicine) after bare-metal stent (BMS) implantation
11), DES implantation may be associated with a
reater risk of aneurysm formation. However, the
rue incidence, clinical course, and treatment of cor-
nary artery aneurysms after DES implantation re-
ain largely unknown. Therefore, in this review, it is
ur goal to summarize the current status of coronary
rtery aneurysms after DES implantation from the
ublished medical literature.
iagnosis of Coronary Artery Aneurysms
fter Stent Implantation
oronary intervention-associated aneurysms usu-
lly are detected at the time of repeat angiography
or recurrent symptoms or as part of routine
ngiographic follow-up as mandated by study pro-
ocols. Coronary angiography is the gold standard
or the diagnosis of coronary aneurysms, which are
efined as a luminal dilation 50% larger than that
f the adjacent reference segment (3,12,13). How-
ver, coronary angiography provides only luminal
nformation and cannot visualize other structures,
i
t
a
s
d
a
s
a
c
a
t
g
a
c
t
i
u
i
i
P
A
I
f
a
D
D
i
n
t
i
c
(
c
i
t
h
o
r
p
r
a
a
p
a
D
s
c
a
p
t
p
t
a
a
(
f
t
c
t
t
m
I
B
I
a
p
(
a
c
d
e
F
r
v
r
a
e
t
c
o
w
1
v
e
r
p
s
e
s
a
t
p
u
q
e
t
m
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 1 , 2 0 0 8
F E B R U A R Y 2 0 0 8 : 1 4 – 2 1
Aoki et al.
Aneurysms After DES
15ncluding the layers of the arterial wall. Further discrimina-
ion between true aneurysms and pseudoaneurysms, as well
s detection of the aneurysm entry site (sometimes caused by
tent edge dissection or stent edge injury at acute bends
uring vessel movement), are important to optimally man-
ge aneurysms after coronary intervention.
Intravascular ultrasound (IVUS) has become the “gold
tandard” in providing critical diagnostic information to
ddress these anatomic considerations in the evaluation of
oronary aneurysms (Fig. 1) (14–16). Furthermore, other
dvanced coronary imaging techniques, such as computed
omography angiography, coronary magnetic resonance an-
iography, and real-time 3-dimensional echocardiography,
lso can be used as tools to detect and follow certain
oronary aneurysms noninvasively (17–21), and computed
omography angiography may be the most effective of these
n the milieu of metal stent artifacts (Fig. 2) (22). Contin-
ous technological evolution in the field of noninvasive
maging is expected to enhance the clinically relevant
nformation derived from these studies.
athophysiology of Aneurysm Formation
fter DES Implantation
n addition to the mechanical risk factors for aneurysm
ormation that are observed with both BMS and DES, there
re other potential mechanisms that may be specific to
ES. Inflammatory reactions in response to implanted
ES have been postulated as 1 such factor. Although
nflammatory and allergic reactions to nickel and molybde-
um have been reported after BMS implantation (23), the
riggers for inflammatory and allergic reactions after DES
mplantation are more complex because DES consist of 3
omponents: the antirestenotic drug, the drug carrier vehicle
polymer), and the stent platform. In particular, the polymer
arrier has been shown to provoke eosinophilic/heterophilic
nfiltration and induce a marked inflammatory reaction of
he arterial wall (8,24,25). Several histological studies
ave shown extensive inflammation consisting primarily
f eosinophilis and lymphocytes with a focal giant cell
eaction around the stent struts and surrounding the
olymer after DES implantation (8,9). Among these
eports, Virmani et al. (8) presented an autopsy case with
neurysmal dilation of the stented arterial segments with
severe localized hypersensitivity reaction consisting
redominantly of T lymphocytes and eosinophils through
ll layers of the vessel wall.
In addition, delayed healing reactions in response to
ES, such as incomplete endothelialization over DES
truts, have been detected by invasive approaches (angios-
opy and optical coherence tomography) as well as in
utopsy studies (9,26–28). Whether the presence of incom-
lete endothelialization is a precursor of aneurysm forma-
ion or just a sign of vessel injury is unknown, but this mhenomenon has not been described after BMS implanta-
ion. An additional phenomenon that has been observed
fter DES implantation is late acquired incomplete stent
pposition, which is observed in 8% to 10% of patients
29,30). Although it may be a precursor of aneurysm
ormation, the exact nature of the relationship between
hese 2 findings remains to be determined. In short, the
ombination of physical trauma induced by stent implanta-
ion and specific biological reactions after DES implanta-
ion might together contribute to coronary aneurysm for-
ation after DES implantation.
ncidence of Coronary Artery Aneurysms in
MS Versus DES Randomized Trials
n the pivotal DES versus BMS randomized trials, routine
ngiographic follow-up was performed in a large subset of
atients at 6 to 9 months after the initial procedure
5,6,31–33). In these trials, the definition of coronary artery
neurysms was vessel distension of 20% or more in diameter
ompared with the reference vessel at follow-up, a stricter
efinition compared with the definition used in the BMS
ra (vessel distension of 50%).
igure 3 depicts odds ratios and
espective 95% confidence inter-
als for coronary artery aneu-
ysms in association with DES
nd BMS derived from a fixed-
ffects meta-analytic model. In
his analysis, the incidence of
oronary aneurysms was similar
verall with DES compared
ith BMS (1.1% [18 of 1,615] with DES and 0.8% [12 of
,587] with BMS [odds ratio 1.326, 95% confidence inter-
al 0.571 to 3.078; p  0.512]).
There are several notable caveats to these crude frequency
stimates. First, these data are derived from the pivotal
andomized trials of DES versus BMS, which enrolled
atients with simple, de novo coronary lesions who met
trict entry criteria. In addition, the relative rarity of overall
vents (reflected in the wide confidence intervals of the
ummary estimate) makes it difficult to definitively rule out
treatment effect upon aneurysm formation. Additionally,
hese data are derived from early angiographic follow-up of
atients enrolled in these trials and, at this point, it remains
nclear whether late aneurysm formation occurs more fre-
uently in 1 treatment group compared with another. For
xample, a case report of acquired incomplete stent apposi-
ion after DES implantation described late aneurysm for-
ation 18 months after the initial procedure (22). Further-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CTA  computed
tomography angiography
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasoundore, it is currently unknown whether DES or BMS
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16redispose to different types of aneurysm formation (such as
seudo vs. true aneurysms, and saccular vs. nonsaccular).
oronary Artery Aneurysms After DES or BMS
mplantation Outside of Randomized Trials
n estimate of the actual incidence of coronary artery
neurysm formation after BMS or DES implantation out-
ide of randomized trials has been reported in only 2
bstracts. Kachru et al. (34) reported an incidence of 0.2% (4
f 2,408) per DES without routine angiographic follow-up
nd Rha et al. (35) reported an incidence of 1.7% (5 of 296)
er patient at 6-month routine angiographic follow-up.
owever, the overall incidence of coronary artery aneurysms
fter DES in the “real world” is unclear due to the limited
ata.
There have been several case reports of coronary aneu-
ysms occurring after DES or BMS implantation (Tables 1
nd 2) (36–70). Similar to the case reports of aneurysm
ormation after BMS implantation, the clinical course of
atients with coronary artery aneurysms after DES implan-
ation is variable. Moreover, these published reports dem-
nstrate that in some cases, aneurysms may naturally resolve
46). Overall, coronary aneurysms were detected from 3 days
o up to 4 years after the initial procedure for DES and 6
ays to up to 9 years for BMS, and patients had variable
Figure 1. Angiographic and IVUS Images of Coronary Artery Aneurysm
(A and B) Coronary artery aneurysm detected by coronary angiography and in
(C and D) Coronary artery aneurysm detected with coronary angiography andlinical presentations. aroposed Classification of
oronary Artery Aneurysms
n the basis of a review of the published literature, 3
ifferent types of aneurysms after DES or BMS implanta-
ion have been described. Although there are no data
egarding the prognostic import of differing aneurysm types,
system of aneurysm classification may be useful to guide
herapies because some coronary aneurysms are fatal with-
ut prompt and appropriate treatment (39,71,72), and some
oronary aneurysms are not life-threatening events and need
nly careful observation without treatment (41,45,46,51).
What we have termed a type I aneurysm is a type of
neurysm that demonstrates rapid early growth with pseu-
oaneurysm formation detected within 4 weeks (36,38,58).
his type is typically complicated by clinical pericarditis.
iven the rapid time course of aneurysm formation, it is
ikely that arterial injury related to the procedure is the likely
ontributor to aneurysm formation in these cases rather than
he chronic arterial response to the stent, polymer, and drug.
The second kind of aneurysm described in the literature
s that with a “subacute to chronic” presentation (type II)
nd is typically detected incidentally during angiography for
ecurrent symptoms or as part of protocol mandated
ollow-up (usually detected 6 months after the procedure)
15,40–47,49–55,59,60,62–70). These aneurysms appear
o have the most varied clinical presentations; some patients
cular ultrasound (IVUS) at 8 months after bare-metal stent implantation.
at 3 months after drug-eluting stent implantation.travasre asymptomatic, but some have complaints of angina. It
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17eems more likely in this scenario that a chronic arterial
esponse to a metal stent, polymer, and/or drug, may be the
asis for aneurysm formation in this subtype.
Figure 2. Angiographic and CTA Images of
Coronary Artery Aneurysm After DES Implantation
Coronary artery aneurysm at 18 months after drug-eluting stent (DES)
implantation. Adapted from Degertekin et al. (22). CTA  computed
tomography angiography.
Figure 3. Odds Ratios and Their 95% CIs of Coronary Artery Aneurysm Ass
The odds ratios are shown on a logarithmic scale. The size of the square is pro
variance in the study by the Mantel-Haenszel procedure. BMS  bare-metal st
SIRIUS  SIRolImUS-coated Bx Velocity balloon expandable stent in the treatment oThe final reported subtype in the published literature is
ycotic or infectious in etiology (type III) (37,39,
8,56,57,61). Large mycotic aneurysms infected with Staph-
lococcus aureus after DES or BMS implantation have been
eported. In these rare cases, patients typically present with
ystemic manifestations and fever as the result of bactere-
ia. Whether the local immunosuppressive effects of eluted
rugs from stents tend to increase the incidence of these rare
nfectious aneurysms is unknown.
roposed Treatment of
oronary Artery Aneurysms
single study has reported similar 5-year mortality of
atients with chronic native coronary aneurysms compared
ith patients without coronary aneurysms (73). However,
he applicability of these data to intervention-associated
neurysms may not be appropriate. Iatrogenic dissections
nd deep arterial injury caused by the interventional proce-
ures are the potential foundations of pseudoaneurysms,
hich may lead to rupture. In addition, turbulent and
luggish flow in the vicinity of the aneurysm that contains a
etallic stent might be associated with stent thrombosis or
istal embolism (53,74). Nevertheless, given the rarity of
verall events as well as the lack of published data on the
anagement of coronary artery aneurysms secondary to
tent implantation and the absence of natural history data of
ntreated coronary aneurysms after stents, treatment strat-
gies remain controversial and somewhat based on case-by-
ase “best clinical judgment” decisions. What complicates
he clinical decision-making process further is the fact that
omplete resolution of these aneurysms has been observed in
d With DES Versus BMS
nal to the weight of the individual studies, measured as the inverse of the
I  conﬁdence interval; DES  drug-eluting stent; MR  moderate release;ociate
portio
ent; Cf patients with de novo coronary artery lesions; SR  slow release.
s
o
“
e
c
a
a
a
c
a
C
a
a
r
t
r
a
v
e
i
t
a
f
itis; PES
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 1 , 2 0 0 8
F E B R U A R Y 2 0 0 8 : 1 4 – 2 1
Aoki et al.
Aneurysms After DES
18ome cases without treatment in contrast to the possibility
f rupture if the aneurysm is left untreated.
We propose that treatment of coronary aneurysms be
individualized” using a combination of aneurysm size,
xpansion history, pathophysiology, and symptoms to de-
ide when and if to apply therapy alternatives (Fig. 4). It is
lso important to consider that therapy options for coronary
neurysms are somewhat controversial as well, because there
re few data with interventional modalities (stent grafts or
oils), and surgery may be problematic depending upon the
neurysm location and the clinical state of the patient.
oncerns relating to stent graft treatment of coronary
Table 1. Published Case Reports of Coronary Artery Aneurysms After DES
Authors (Ref. #) Age (yrs) Gender
Clinical Presentation
at the Initial
Treatment Type of
Gupta et al. (36) 32 M AP
(BMS ISR lesion)
SES
Gupta et al. (36) 55 M OMI SES
Jindal et al. (37) 66 M ACS
(DES ISR lesion)
SES
Zhang et al. (38) 44 M AP PES
Singh et al. (39) 56 M AP SES
Panja et al. (40) 58 M ACS SES
Nilsen et al. (41) 55 F AP PES
Kaul et al. (42) 75 F ACS SES
Anandaraja et al. (43) 45 F ACS PES
Vik-Mo et al. (44) 43 M AP PES
Kim et al. (45) 63 F AP PES
Kim et al. (46) 54 F AP PES
Bavry et al. (47) 45 M N/A PES
Le et al. (48) 73 M ACS
(SES ISR lesion)
PES
Stabile et al. (49) 52 F ACS SES
Bavry et al. (47) 49 F N/A SES
Li et al. (50) 12 F Kawasaki disease SES
Abreu et al. (51) 52 M ACS SES
Bavry et al. (47) 49 F N/A SES
Vaknin-Assa et al. (52) 59 M Stress-induced
ischemia
SES
Bavry et al. (47) 44 M N/A PES
Aziz et al. (53) 70 F ACS SES
Harish et al. (54) 56 M OMI
ISR
SES
Luthra et al. (55) 50 M AMI SES
  aneurysms without in-stent restenosis;   aneurysms with in-stent restenosis; ACS  acute
CABG coronary artery bypass grafting; CHF congestive heart failure; DES drug-eluting stent
artery; LMT left main trunks; N/A not available; OMI old myocardial infarction; PE pericardneurysms include closure of contiguous side branches mrising next to the aneurysm site, stent thrombosis, and
ecurrent restenosis. Placing coronary coils behind stents to
hrombose the aneurysm sac can also be challenging and
equires considerable expertise.
For pseudoaneurysms detected by IVUS (type I) that
re large at presentation (i.e., at least twice the reference
essel diameter) or show significant expansion over time,
specially in the presence of symptoms, we propose
nterventional or surgical treatment. Our threshold for
reatment is lower for pseudoaneurysms than for true
neurysms, because of the presumed greater likelihood
or rupture. For large true aneurysms (type II), again
tation
Vessel Timing Symptom ISR Treatment
LAD 3 days ACS
PE ()
 CABG
Aneurysm repair
LAD 2 weeks ACS
PE ()
 CABG
Aneurysm repair
LAD 2 weeks Fever
PE ()
 CABG
Aneurysm repair
LAD 30 days No symptom  Observation
LAD 5 weeks AMI
Sepsis
 CABG
LAD 6 weeks ACS  CABG
Aneurysm repair
LAD 2 months AP  Observation
LAD 6 months AP  CABG
Aneurysm repair
LAD 6 months ACS  N/A
RCA 6 months No symptom  Covered stent
LCX 6 months No symptom  Observation
LAD 6 months No symptom  Observation
Naturally resolved
RCA 6 months N/A  Observation
LMT 7 months CHF
Sepsis
 CABG
Aneurysm repair
LAD/RCA 7 months ACS  BMS
LMT 10 months N/A  Observation
RCA 1 yr No symptom  Observation
LCX 17 months AP  Observation
LCX 19 months N/A  CABG
Aneurysm repair
RCA 20 months AMI  BMS
LCX 21 months N/A  Coiling
LAD 21 months AMI 
Stent thrombosis
BMS
LAD 2 yrs ACS 
Stent fracture
Observation
LAD 4 yrs AP  CABG
Aneurysm repair
ry syndrome; AMI  acute myocardial infarction; AP  angina pectoris; BMS  bare-metal stent;
n-stent restenosis; LAD left anterior descending coronary artery; LCX left circumflex coronary
 paclitaxel-eluting stent; RCA right coronary artery; SES sirolimus-eluting stent.Implan
DES
corona
; ISR iore than twice as large as the reference vessel diameter,
e
v
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19specially with symptoms, we would also propose inter-
entional or surgical treatment to avoid potential life-
hreatening complications, regardless of stent type (BMS
Figure 4. Proposed Treatment Algorithm
Proposed algorithm for the treatment of coronary aneurysm after DES implant
**Less than twice as large as the reference vessel diameter. CABG  coronary
Table 2. Published Case Reports of Coronary Artery Aneurysm After BMS I
Authors (Ref. #) Age (yrs) Gender
Clinical Presentation
at the Initial
Treatment T
Bouchart et al. (56) 38 M ACS P
Liu et al. (57) 72 M AMI N
Nohara et al. (58) 67 M OMI W
Cafri et al. (59) 53 F ACS G
Lubell et al. (60) 39 M AMI N
Leroy et al. (61) 49 M ACS P
Kishi et al. (62) 42 M AP S
Kitzis et al. (63) 43 M AMI P
Berkalp et al. (64) 47 F ACS N
Nisanci et al. (65) 36 M ACS A
Regar et al. (66) 68 M AP P
Voigtlander et al. (67) 49 M ACS P
Noguchi et al. (68) 60 M ACS P
Oyama et al. (69) 53 M Stress-induced
ischemia
M
Rubartelli et al. (70) N/A N/A ACS P
Porto et al. (15) 65 F AMI P
Abbreviations as in Table 1.sound; other abbreviations as in Figure 3.r DES). We would have a somewhat lower threshold for
reating DES aneurysms compared with BMS aneu-
ysms. However, the true clinical course of type II
*More than and equal to twice as large as the reference vessel diameter;
bypass grafting; CT  computed tomography; IVUS  intravascular ultra-
tation
BMS Vessel Timing Symptom ISR Treatment
Schatz LCX 6 days ACS
Fever
PE ()
 CABG
Aneurysm repair
LAD 18 days AP
Fever
 CABG
Aneurysm repair
LAD 1 month No symptom  CABG
Aneurysm repair
LAD 6 weeks AP  N/A
LAD 2 months AP  N/A
Schatz LAD 10 weeks CHF
Fever
 CABG
Aneurysm repair
RCA 3 months No symptom  Covered stent
Schatz LCX 3 months ACS  BMS
RCA 4 months No symptom  Observation
ro LAD 6 months No symptom  Observation
Schatz LAD 6 months AP  CABG
Schatz LAD 6 months No symptom  Observation
Schatz LCX 6 months No symptom  N/A
LAD 6 months No symptom  Covered stent
Schatz LCX 1 yr N/A  Covered stent
Schatz RCA 9 yrs AP  BMSation.
arterymplan
ype of
almaz-
IR
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FX
/A
almaz-
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almaz-
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VE mic
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20neurysms is not well defined. Some of these aneurysms,
ven large aneurysms, might be naturally resolved.
We propose immediate surgical therapy for any con-
rmed infected aneurysm (type III). In addition, it must be
aken into account that meticulous handling techniques
i.e., washing of gloves and hands, wearing a mask, and
inimal handling of catheters and guidewires) and steril-
zation of the operating room may minimize the risk of
acterial contamination that results in infected aneurysms.
inally, long-term antithrombotic drug therapy, such as
spirin and clopidogrel, should be necessary to reduce the
isk of stent thrombosis and distal embolism in patients with
oronary artery aneurysms. Clearly, there is no consensus
egarding the treatment algorithm and our proposal is not
ased on prospective data, underscoring the need for further
tudy of this relatively infrequent phenomenon.
onclusions
oronary artery aneurysms after DES implantation are rare,
ith an incidence of 0.2% to 2.3% in the DES and BMS
ivotal randomized trials. The clinical course of coronary
rtery aneurysms after DES implantation is variable. Some
neurysms naturally resolve, but some aneurysms can lead to
ife-threatening complications. Although the best treatment
or coronary aneurysms after DES is controversial, we
ropose that a combination of aneurysm size, expansion
istory, pathophysiology, and symptoms be used to decide
n treatment. Expanding pseudoaneurysms, infected aneu-
ysms, and large, chronic (and expanding) aneurysms with
ymptoms should be treated. Further investigation is nec-
ssary to determine the pathophysiology, natural history,
nd best therapies for DES-associated aneurysms.
eprint requests and correspondence: Dr. George Dangas,
ssociate Professor of Clinical Medicine, Columbia University
edical Center, 111 East 59th Street, 11th Floor, New York,
ew York 10022. E-mail: gdangas@crf.org.
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